OMass Therapeutics
Generated by Meeveem AI
"Discovering medicines against validated membrane protein targets in immunology and rare diseases"
About OMass Therapeutics
OMass Therapeutics discovers small-molecule medicines targeting membrane proteins and intracellular complexes in immunological and rare diseases. Its platform combines proprietary biochemistry, native mass spectrometry and custom chemistry to study targets within their biological ecosystems. By preserving protein partners, lipid interactions and regulatory molecules, it combines biological relevance with precise measurements of binding and function.
Founded in 2016 and based in Oxford, OMass advances programmes involving solute carriers, GPCRs and inflammasome complexes. Its pipeline includes targets for rare endocrine disorders, lupus and inflammatory bowel disease. The University of Oxford spin-out brings together multiple scientific disciplines to investigate targets that conventional drug-discovery methods can struggle to address.
Working across disciplines
OMass describes drug discovery as a team enterprise, with specialists sharing expertise across scientific disciplines. Scientific and operations teams support the same research goals, and the company’s Oxford workplace brings them together on one site. Its careers material describes regular contact with patient groups and advocates to connect day-to-day work with the conditions being studied.
Development shaped around the individual
Managers support personalised development plans and regular feedback. OMass describes support for conferences, courses or professional qualifications when these address an identified development need and benefit both the individual and the business. Learning also comes through working with colleagues across disciplines, giving team members exposure to the wider drug-discovery process.
60
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment